European guidelines on cardiovascular disease prevention in clinical practice: executive summary

Guidelines and Expert Consensus Documents summarize and evaluate all currently available evidence on a particular issue with the aim to assist physicians in selecting the best management strategies for a typical patient, suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are not substitutes for textbooks. The legal implications of medical guidelines have been discussed previously. A great number of Guidelines and Expert Consensus Documents have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organizations. Because of the impact on clinical practice, quality criteria for development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines and Expert Consensus Documents can be found on the ESC web site (http://www.escardio.org/knowledge/guidelines/rules). In brief, experts in the field are selected and undertake a comprehensive review of the published evidence for management and/or prevention of a given condition. A critical evaluation of diagnostic and therapeutic procedures is performed, including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger societies are included, where data exist. The level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to predefined scales, as outlined in the tables below. The experts of the writing panels have provided disclosure statements of all relationships they may have which might be perceived as real or potential sources of conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. Any changes in conflict of interest that arise during the writing period must be notified to the ESC. The Task Force report was entirely …

[1]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[2]  Ulf Risérus,et al.  Sagittal abdominal diameter as a marker of inflammation and insulin resistance among immigrant women from the Middle East and native Swedish women: a cross-sectional study , 2007, Cardiovascular diabetology.

[3]  D. Medeiros,et al.  Dietary Reference Intakes: the Essential Guide to Nutrient Requirements edited by JJ Otten, JP Hellwig, and LD Meyers, 2006, 560 pages, hardcover, $44.96. The National Academies Press, Washington, DC. , 2007 .

[4]  P. Poole‐Wilson,et al.  Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET) , 2007, Heart.

[5]  D. Conrad,et al.  Global variation in copy number in the human genome , 2006, Nature.

[6]  C. Wiysonge,et al.  How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis , 2006, Journal of hypertension.

[7]  Deborah F Tate,et al.  A self-regulation program for maintenance of weight loss. , 2006, The New England journal of medicine.

[8]  S. Humphries,et al.  Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes , 2006, Journal of medical screening.

[9]  A. Victor,et al.  Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels – a study in twins , 2006, Genes and Immunity.

[10]  Samuel Wann,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ , 2006, European heart journal.

[11]  T. Heise,et al.  Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients , 2006, Journal of hypertension.

[12]  Alastair Gray,et al.  Economic burden of cardiovascular diseases in the enlarged European Union. , 2006, European heart journal.

[13]  G. Mancia,et al.  Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial , 2006, Journal of hypertension.

[14]  Peter Lindgren,et al.  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary , 2007 .

[15]  A. Eckardstein Differential diagnosis of familial high density lipoprotein deficiency syndromes. , 2006 .

[16]  Andy McEwen,et al.  Manual of Smoking Cessation , 2006 .

[17]  G. Lowe,et al.  Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture * , 2006, British journal of haematology.

[18]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[19]  Mats Börjesson,et al.  ESC Study Group of Sports Cardiology: recommendations for participation in leisure-time physical activity and competitive sports for patients with ischaemic heart disease , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[20]  Silvia G Priori,et al.  Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. , 2006, European heart journal.

[21]  L. Ruilope,et al.  Chronic kidney disease as a situation of high added risk in hypertensive patients. , 2006, Journal of the American Society of Nephrology : JASN.

[22]  S. Humphries,et al.  Investigating the Genetic Determinants of Cardiovascular Disease Using Candidate Genes and Meta‐analysis of Association Studies , 2006, Annals of human genetics.

[23]  Rodney A. White,et al.  ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography , 2006, Circulation.

[24]  John Danesh,et al.  Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls , 2006, The Lancet.

[25]  Paul Poirier,et al.  Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism , 2006, Circulation.

[26]  M. Briel,et al.  Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.

[27]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[28]  L. Smeeth,et al.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis , 2005, The Lancet.

[29]  Jean-Claude Tardif,et al.  Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. , 2005, European heart journal.

[30]  Oscar H Franco,et al.  Effects of physical activity on life expectancy with cardiovascular disease. , 2005, Archives of internal medicine.

[31]  T. Berl,et al.  Kidney-heart interactions: epidemiology, pathogenesis, and treatment. , 2005, Clinical journal of the American Society of Nephrology : CJASN.

[32]  Lisa Hartling,et al.  Meta-Analysis: Secondary Prevention Programs for Patients with Coronary Artery Disease , 2005, Annals of Internal Medicine.

[33]  L. Lindholm,et al.  Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis , 2005, The Lancet.

[34]  E. Braunwald,et al.  Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.

[35]  Ž. Reiner,et al.  Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. , 2005, The American journal of cardiology.

[36]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[37]  M. Khoury,et al.  How many genes underlie the occurrence of common complex diseases in the population? , 2005, International journal of epidemiology.

[38]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[39]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[40]  L. Peltonen,et al.  USF1 and dyslipidemias: converging evidence for a functional intronic variant. , 2005, Human molecular genetics.

[41]  L. Getz,et al.  Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study , 2005, BMJ : British Medical Journal.

[42]  D. Brancaccio,et al.  Pathogenesis of vascular calcification in chronic kidney disease. , 2005, Kidney international.

[43]  S. Priori,et al.  Gender-specific prescription for cardiovascular diseases? , 2005, European heart journal.

[44]  G. Lowe Circulating inflammatory markers and risks of cardiovascular and non‐cardiovascular disease , 2005, Journal of thrombosis and haemostasis : JTH.

[45]  S. Humphries,et al.  Implementation of cascade testing for the detection of familial hypercholesterolaemia , 2005, Current opinion in lipidology.

[46]  M. Goldacre,et al.  Trends in mortality and hospital admission rates for abdominal aortic aneurysm in England and Wales, 1979–1999 , 2005, The British journal of surgery.

[47]  Jackie A Cooper,et al.  A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. , 2005, Atherosclerosis.

[48]  K. Berge,et al.  Identification of deletions and duplications in the low density lipoprotein receptor gene by MLPA. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[49]  Jean-Claude Tardif,et al.  Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. , 2005, European heart journal.

[50]  R. Coleman,et al.  Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. , 2005, JAMA.

[51]  Thierry Troosters,et al.  How to assess physical activity? How to assess physical fitness? , 2005, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[52]  Karina W Davidson,et al.  The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. , 2005, Journal of the American College of Cardiology.

[53]  Ž. Reiner,et al.  [Concomitant use of statins and cytochrome P 450 inhibitors in Croatia]. , 2005, Liječnički vjesnik.

[54]  L. Melvin,et al.  Effects of estrogen with and without progestin on urinary incontinence , 2005, Journal of Family Planning and Reproductive Health Care.

[55]  A. Geelen,et al.  Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans. , 2005, The American journal of clinical nutrition.

[56]  E. Lewis,et al.  Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[57]  A. Bikhazi,et al.  Effect of insulin and angiotensin II receptor subtype-1 antagonist on myocardial remodelling in rats with insulin-dependent diabetes mellitus , 2005, Journal of hypertension.

[58]  G. Mancia,et al.  Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection , 2005, Blood pressure.

[59]  R. Hubbard,et al.  Risk of myocardial infarction and stroke after acute infection or vaccination. , 2004, The New England journal of medicine.

[60]  J. Craig,et al.  Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. , 2004, Journal of the American Society of Nephrology : JASN.

[61]  G. Remuzzi,et al.  Preventing microalbuminuria in type 2 diabetes. , 2004, The New England journal of medicine.

[62]  David B Allison,et al.  Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. , 2004, Circulation.

[63]  M. Tonelli,et al.  The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. , 2004, Journal of the American College of Cardiology.

[64]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[65]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[66]  F. Magrini,et al.  Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis: Results of a Randomized Trial , 2004, Circulation.

[67]  D. Bacquer,et al.  Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys , 2004, Diabetologia.

[68]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[69]  Ž. Reiner,et al.  Atherosclerosis of retinal arteries in men: role of serum lipoproteins and apoproteins. , 2004, Croatian medical journal.

[70]  P. Sweetnam,et al.  Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies. , 2004, European heart journal.

[71]  J. Brunzell,et al.  Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. , 2004, The Journal of clinical endocrinology and metabolism.

[72]  Gösta Samuelson,et al.  Global strategy on diet, physical activity and health , 2004 .

[73]  S. Ebrahim,et al.  Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. , 2004, The American journal of medicine.

[74]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[75]  Philippa J Talmud,et al.  Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation? , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[76]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[77]  L. Peltonen,et al.  Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1) , 2004, Nature Genetics.

[78]  Daniel Levy,et al.  Predictors of new-onset kidney disease in a community-based population. , 2004, JAMA.

[79]  Constance K Haan,et al.  Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Circulation.

[80]  C. Herrmann-Lingen,et al.  Screening for psychosocial risk factors in patients with coronary heart disease-recommendations for clinical practice , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[81]  T. Leren,et al.  Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. , 2004, Seminars in vascular medicine.

[82]  F. Civeira,et al.  Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. , 2004, Seminars in vascular medicine.

[83]  K. Eagle,et al.  Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. , 2004, Journal of vascular surgery.

[84]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[85]  S. Blankenberg,et al.  Interleukin-18 and the Risk of Coronary Heart Disease in European Men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) , 2003, Circulation.

[86]  F. Turnbull Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[87]  S. Yusuf,et al.  Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[88]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[89]  H. Diener,et al.  European Stroke Initiative Recommendations for Stroke Management – Update 2003 , 2003, Cerebrovascular Diseases.

[90]  G. Mancia,et al.  European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) , 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[91]  W. Ambrosius,et al.  Older adults with chronic disease: benefits of group-mediated counseling in the promotion of physically active lifestyles. , 2003, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[92]  R. Schmieder,et al.  A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. , 2003, The American journal of medicine.

[93]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[94]  Peter W de Leeuw,et al.  Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. , 2003, The New England journal of medicine.

[95]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[96]  R. Pandey,et al.  Non-obese (body mass index < 25 kg/m2) Asian Indians with normal waist circumference have high cardiovascular risk. , 2003, Nutrition.

[97]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[98]  E. Hawe,et al.  Family History is a Coronary Heart Disease Risk Factor in the Second Northwick Park Heart Study , 2003, Annals of human genetics.

[99]  V. Gudnason,et al.  Systematic Family Screening for Familial Hypercholesterolemia in Iceland , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[100]  Yu-ling,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[101]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[102]  RAP Scott,et al.  The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial , 2002, The Lancet.

[103]  G. Mancia,et al.  Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial , 2002, Circulation.

[104]  H. Arnesen,et al.  Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.

[105]  M. Nieminen,et al.  Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study , 2002, Journal of hypertension.

[106]  AndrewJ. S. Coats MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[107]  N. Martin,et al.  Heritabilities of apolipoprotein and lipid levels in three countries. , 2002, Twin research : the official journal of the International Society for Twin Studies.

[108]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[109]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[110]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[111]  P. Mehler,et al.  Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. , 2002, Kidney international.

[112]  G. Assmann,et al.  Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002, Circulation.

[113]  R. Peto,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[114]  Daniel Levy,et al.  Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study , 2001, The Lancet.

[115]  J. Kastelein,et al.  The molecular basis of familial hypercholesterolemia in The Netherlands , 2001, Human Genetics.

[116]  G. Norman,et al.  Self-efficacy, psychosocial factors, and exercise behavior in traditional versus modified cardiac rehabilitation. , 2001, Journal of cardiopulmonary rehabilitation.

[117]  P. Armstrong,et al.  Randomised trials of secondary prevention programmes in coronary heart disease: systematic review , 2001, BMJ : British Medical Journal.

[118]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[119]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[120]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[121]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[122]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[123]  Lawrence Joseph,et al.  β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis , 2001 .

[124]  S. Humphries,et al.  A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom , 2001, European Journal of Human Genetics.

[125]  D. Wood,et al.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.

[126]  N. Chaturvedi Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. , 2001, Annals of internal medicine.

[127]  J. Pankow,et al.  Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. , 2001, Atherosclerosis.

[128]  J. Porter,et al.  The American Association for Vascular Surgery. , 2001, Cardiovascular surgery.

[129]  T. Pischon,et al.  Hypothesis: β-Adrenergic Receptor Blockers and Weight Gain , 2001 .

[130]  E. Sijbrands,et al.  Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands , 2001, The Lancet.

[131]  G. Bray,et al.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet , 2001 .

[132]  B. Wajchenberg Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. , 2000, Endocrine reviews.

[133]  A. Astrup,et al.  Obesity : Preventing and managing the global epidemic , 2000 .

[134]  B. Conrad,et al.  Relationship Between Circadian Blood Pressure Patterns and Progression of Early Carotid Atherosclerosis: A 3-Year Follow-Up Study , 2000, Circulation.

[135]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[136]  T. Sellers,et al.  Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. , 2000, Archives of internal medicine.

[137]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[138]  Eduard Diogène,et al.  β-Adrenergic Blocking Agents in Heart Failure: Benefits of Vasodilating and Nonvasodilating Agents According to Patients' Characteristics: A Meta-analysis of Clinical Trials , 2000 .

[139]  Karla Kerlikowske,et al.  Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials , 2000, The Lancet.

[140]  E. Vartiainen,et al.  Cardiovascular risk factor changes in Finland, 1972-1997. , 2000, International journal of epidemiology.

[141]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[142]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[143]  J. Martínez,et al.  Physical inactivity, sedentary lifestyle and obesity in the European Union , 1999, International Journal of Obesity.

[144]  M. Awerbuch Non-specific arm pain , 1999, The Lancet.

[145]  I. Jialal,et al.  GISSI-Prevenzione trial , 1999, The Lancet.

[146]  J. Meulman,et al.  A meta-analysis of psychoeducational programs for coronary heart disease patients. , 1999 .

[147]  M. Burnier,et al.  Compliance with antihypertensive therapy. , 1999, Clinical and experimental hypertension.

[148]  Nick Freemantle,et al.  β Blockade after myocardial infarction: systematic review and meta regression analysis , 1999 .

[149]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[150]  L. Smeeth,et al.  Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading , 1999, BMJ.

[151]  K. McDonald,et al.  Meta-analysis of Trials Comparing β-Blockers, Calcium Antagonists, and Nitrates for Stable Angina , 1999 .

[152]  H. Tunstall-Pedoe,et al.  Contribution of trends in survival and coronar y-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations , 1999, The Lancet.

[153]  G. Lowe,et al.  Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. , 1999, European heart journal.

[154]  P. Brocklehurst Infection and preterm delivery , 1999, BMJ.

[155]  J. Grimshaw,et al.  Potential benefits, limitations, and harms of clinical guidelines , 1999, BMJ.

[156]  W A Kalender,et al.  Electrocardiogram-correlated image reconstruction from subsecond spiral computed tomography scans of the heart. , 1998, Medical physics.

[157]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[158]  A. Zanchetti,et al.  The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long‐term randomized treatment with either verapamil or chlorthalidone on carotid intima‐media thickness , 1998, Journal of hypertension.

[159]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[160]  Ian Graham,et al.  Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. , 1998, European heart journal.

[161]  A. Jacobs,et al.  Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI) , 1998, Circulation.

[162]  Siep Thomas,et al.  Attributes of clinical guidelines that influence use of guidelines in general practice: observational study , 1998, BMJ.

[163]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[164]  Jenny Field,et al.  General practitioners' perceptions of the route to evidence based medicine: a questionnaire survey , 1998, BMJ.

[165]  G. Guyatt,et al.  Effect of HMGcoA Reductase Inhibitors on Stroke , 1998, Annals of Internal Medicine.

[166]  G. Smith,et al.  Meta-analysis Spurious precision? Meta-analysis of observational studies , 1998, BMJ.

[167]  N J Wald,et al.  Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence , 1997, BMJ.

[168]  H. Levine Rest heart rate and life expectancy. , 1997, Journal of the American College of Cardiology.

[169]  Roberto Sega,et al.  Blood-pressure control in the hypertensive population , 1997, The Lancet.

[170]  M. Rocco,et al.  Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. , 1996, JAMA.

[171]  W. Kannel Blood pressure as a cardiovascular risk factor: prevention and treatment. , 1996, JAMA.

[172]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[173]  B. Lernfelt,et al.  15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.

[174]  W. Linden,et al.  Psychosocial interventions for patients with coronary artery disease: a meta-analysis. , 1996 .

[175]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[176]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[177]  R. Raiteri,et al.  Anthropometric or ultrasonic measurements in assessment of visceral fat? A comparative study. , 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[178]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice , 1994 .

[179]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. , 1994, European heart journal.

[180]  E. Vartiainen,et al.  Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland , 1994, BMJ.

[181]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[182]  M Alpsten,et al.  A multicompartment body composition technique based on computerized tomography. , 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[183]  A Tremblay,et al.  Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. , 1994, The American journal of cardiology.

[184]  M. Egger,et al.  Who benefits from medical interventions? , 1994, BMJ.

[185]  N. B. Myant Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. , 1993, Atherosclerosis.

[186]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[187]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[188]  K. Caidahl,et al.  Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. CONSENSUS II Multi-Echo Study Group. , 1993, The American journal of cardiology.

[189]  G Mancia,et al.  Prognostic value of 24-hour blood pressure variability , 1993, Journal of hypertension.

[190]  M. Leppert,et al.  Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. , 1993, The American journal of cardiology.

[191]  P. Macfarlane,et al.  Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men. , 1993, British heart journal.

[192]  R S Paffenbarger,et al.  The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. , 1993, The New England journal of medicine.

[193]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[194]  R. Neuwirth,et al.  Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. , 1992, JAMA.

[195]  R. Krauss,et al.  Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes. , 1992, American Journal of Human Genetics.

[196]  R Guardo,et al.  Quantification of adipose tissue by MRI: relationship with anthropometric variables. , 1992, Journal of applied physiology.

[197]  J. Samet Health benefits of smoking cessation. , 1991, Clinics in Chest Medicine.

[198]  W. Kannel,et al.  Parental history is an independent risk factor for coronary artery disease: the Framingham Study. , 1990, American heart journal.

[199]  C. Procacci,et al.  The contribution of sonography to the measurement of intra‐abdominal fat , 1990, Journal of clinical ultrasound : JCU.

[200]  A Tremblay,et al.  Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. , 1990, Arteriosclerosis.

[201]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[202]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[203]  L. Sjöström,et al.  Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. , 1988, The American journal of clinical nutrition.

[204]  G. Assmann,et al.  The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. , 1988, American heart journal.

[205]  R S Paffenbarger,et al.  Heart rate and cardiovascular mortality: the Framingham Study. , 1987, American heart journal.

[206]  G Parati,et al.  Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. , 1987, Journal of hypertension.

[207]  J. Kjekshus,et al.  Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. , 1986, The American journal of cardiology.

[208]  C. Zarins,et al.  Retarding effect of lowered heart rate on coronary atherosclerosis. , 1984, Science.

[209]  P. Björntorp,et al.  Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. , 1984, British medical journal.

[210]  G. Rose,et al.  Strategy of prevention: lessons from cardiovascular disease. , 1981, British medical journal.

[211]  A. Motulsky,et al.  Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. , 1973, The Journal of clinical investigation.

[212]  D. Patterson,et al.  Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. , 1972, Lancet.

[213]  S. Allender,et al.  European cardiovascular disease statistics , 2008 .

[214]  J. Barth,et al.  Smoking Cessation in Patients With Coronary Heart Disease: Risk Reduction and an Evaluation of the Efficacy of Interventions. , 2007 .

[215]  W. J. Howard Low-Fat Dietary Pattern and Risk of Cardiovascular Disease: The Women's Health Initiative Randomized Controlled Dietary Modification Trial , 2007 .

[216]  D. Kromhout,et al.  Dynamics of cardiovascular and all-cause mortality in Western and Eastern Europe between 1970 and 2000. , 2006, European heart journal.

[217]  G. Bakris,et al.  Cardiometabolic syndrome and chronic kidney disease: what is the link? , 2006, Journal of the cardiometabolic syndrome.

[218]  G. Mancia,et al.  New-onset diabetes and antihypertensive drugs. , 2006, Journal of Hypertension.

[219]  S. Moebus,et al.  Prevalence of Peripheral Arterial Disease – Results of the Heinz Nixdorf Recall Study , 2006, European Journal of Epidemiology.

[220]  A. Evans,et al.  Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study. , 2003, Atherosclerosis.

[221]  S. Yusuf MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[222]  S E Humphries,et al.  Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis. , 2001, Atherosclerosis.

[223]  G. Lowe,et al.  Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease , 1999 .

[224]  Claude Bouchard,et al.  Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary , 1998 .

[225]  L. Wilhelmsen,et al.  Physical activity protects against coronary death and deaths from all causes in middle-aged men. Evidence from a 20-year follow-up of the primary prevention study in Göteborg. , 1997, Annals of epidemiology.

[226]  Philippe Amouyel,et al.  A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .

[227]  R. Collins,et al.  Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. , 1994, British medical bulletin.

[228]  T. Manolio,et al.  Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. , 1992, Annals of epidemiology.

[229]  K. Anderson,et al.  An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.